Canaccord Genuity Group Boosts Repligen (NASDAQ:RGEN) Price Target to $170.00

Repligen (NASDAQ:RGEN) had its price objective lifted by Canaccord Genuity Group from $165.00 to $170.00 in a report issued on Friday,Benzinga reports. The firm currently has a hold rating on the biotechnology company’s stock.

A number of other research analysts also recently commented on the stock. TD Cowen initiated coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Friday. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average target price of $183.36.

Repligen Price Performance

NASDAQ RGEN opened at $158.99 on Friday. The firm’s 50 day moving average price is $155.22 and its two-hundred day moving average price is $148.79. Repligen has a twelve month low of $113.50 and a twelve month high of $203.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, sell-side analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently modified their holdings of RGEN. Champlain Investment Partners LLC grew its stake in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after purchasing an additional 594,189 shares during the last quarter. Groupama Asset Managment boosted its stake in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after purchasing an additional 400,680 shares during the period. Finally, Alyeska Investment Group L.P. bought a new stake in Repligen during the 4th quarter valued at approximately $53,428,000. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.